The Purpose of This Study is to Determine if Tetrodotoxin (TTX) is Effective in the Treatment of Pain Resulting From Chemotherapy Treatment (TTX-CINP-201)

This study has been terminated.
(Interim analysis completed and decided to terminate and proceed to Phase 3 trial.)
Sponsor:
Information provided by (Responsible Party):
Wex Pharmaceuticals Inc.
ClinicalTrials.gov Identifier:
NCT01655823
First received: July 19, 2012
Last updated: June 1, 2015
Last verified: June 2015
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been terminated.
  Estimated Study Completion Date: December 2016
  Primary Completion Date: January 2015 (Final data collection date for primary outcome measure)